SPARC and neoplasm: To sum up, SPARC may directly or indirectly contribute to tumor angiogenesis; therefore, inhibition of SPARC gene expression might be expected to be an anti-angiogenic approach to the treatment of MESO, as EMT and angiogenesis are the top hallmark networks that the SPARC gene is involved with.